精准肿瘤学：去伪存真。
Precision oncology: separating the wheat from the chaff.
作者信息
Remon Jordi, Dienstmann Rodrigo
机构信息
Medical Oncology Department, Centro Integral Oncología Clara Campal Barcelona, HM-Delfos, Barcelona, Spain.
Hospital Vall d'Hebrón, Oncology Data Science (ODysSey) Group, Barcelona, Spain.
出版信息
ESMO Open. 2018 Oct 30;3(6):e000446. doi: 10.1136/esmoopen-2018-000446. eCollection 2018.
Abstract
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients' outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.
摘要
基于下一代测序（NGS）检测的精准肿瘤学在日常临床实践中日益普及。然而，这一策略对患者大规模预后的实际影响仍不明确。在本综述中，我们总结了关于该主题的现有文献、广泛实施NGS的局限性、基因组变异解读的瓶颈以及分子肿瘤委员会的作用。
相似文献
1
Precision oncology: separating the wheat from the chaff.精准肿瘤学：去伪存真。
ESMO Open. 2018 Oct 30;3(6):e000446. doi: 10.1136/esmoopen-2018-000446. eCollection 2018.
2
Molecular tests and target therapies in oncology: recommendations from the Italian workshop.肿瘤学中的分子检测和靶向治疗：来自意大利研讨会的建议。
Future Oncol. 2021 Sep;17(26):3529-3539. doi: 10.2217/fon-2021-0286. Epub 2021 Jul 13.
3
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.晚期癌症患者使用下一代测序和分子肿瘤委员会的建议：来自 KSMO 和 KCSG 精准医学网络小组的报告。
Cancer Res Treat. 2022 Jan;54(1):1-9. doi: 10.4143/crt.2021.1115. Epub 2021 Dec 13.
4
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.将下一代测序技术整合到临床肿瘤学中：策略、前景与陷阱。
ESMO Open. 2016 Nov 18;1(5):e000094. doi: 10.1136/esmoopen-2016-000094. eCollection 2016.
5
Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?尿路上皮肿瘤中常规应用下一代测序检测——我们是否已准备好迈向个体化医学的下一步？
Eur J Cancer. 2021 Mar;146:1-10. doi: 10.1016/j.ejca.2020.12.024. Epub 2021 Jan 31.
6
[The new challenge in oncology: Next-generation sequencing and its application in precision medicine].[肿瘤学的新挑战：下一代测序及其在精准医学中的应用]
An Pediatr (Barc). 2016 Nov;85(5):273.e1-273.e7. doi: 10.1016/j.anpedi.2016.05.006. Epub 2016 Jun 24.
7
Advances in Personalized Oncology.个性化肿瘤学进展
Cancers (Basel). 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862.
8
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).西班牙儿科肿瘤精准医学的现状：西班牙儿科血液学和肿瘤学会（SEHOP）的共识报告。
Clin Transl Oncol. 2022 May;24(5):809-815. doi: 10.1007/s12094-021-02759-7. Epub 2022 Feb 12.
9
Next generation sequencing and the molecular tumor board from the point of view of oncologists.从肿瘤学家角度看新一代测序与分子肿瘤委员会
Cesk Patol. 2021 Summer;57(3):144-146.
10
Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer.下一代测序技术在临床肿瘤学中的应用以推动癌症的个性化治疗。
Chin J Cancer. 2012 Oct;31(10):463-70. doi: 10.5732/cjc.012.10216. Epub 2012 Sep 17.
引用本文的文献
1
Reporting of somatic variants in clinical cancer care: recommendations of the Swiss Society of Molecular Pathology.临床癌症护理中体细胞变异的报告：瑞士分子病理学会的建议
Virchows Arch. 2024 Dec;485(6):1033-1039. doi: 10.1007/s00428-024-03951-0. Epub 2024 Oct 23.
2
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis.德国一项针对晚期非小细胞肺癌患者的全国性精准医疗项目有效性评估：一项历史性队列分析
Lancet Reg Health Eur. 2023 Nov 22;36:100788. doi: 10.1016/j.lanepe.2023.100788. eCollection 2024 Jan.
3
Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement.癌症患者中新一代测序检测的实用性及真实世界结果：一项关于基于临床判断进行选择的影响的观察性研究
EClinicalMedicine. 2023 Jun 1;60:102029. doi: 10.1016/j.eclinm.2023.102029. eCollection 2023 Jun.
4
Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital.晚期癌症患者的综合基因组分析及其治疗意义：一所学术医院的经验
Diagnostics (Basel). 2023 May 3;13(9):1619. doi: 10.3390/diagnostics13091619.
5
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.根据 ESMO 分子靶向治疗临床可操作性量表，对难治性结直肠癌进行基因组匹配治疗：综合癌症中心网络的经验。
Mol Oncol. 2023 Sep;17(9):1908-1916. doi: 10.1002/1878-0261.13444. Epub 2023 Jun 12.
6
testing in cholangiocarcinoma: translating molecular studies into clinical practice.在胆管癌中的检测：将分子研究转化为临床实践。
Pathologica. 2023 Apr;115(2):71-82. doi: 10.32074/1591-951X-859. Epub 2023 Apr 5.
7
Precision Oncology in Canada: Converting Vision to Reality with Lessons from International Programs.加拿大精准肿瘤学：从国际项目中吸取经验，将愿景转化为现实。
Curr Oncol. 2022 Sep 30;29(10):7257-7271. doi: 10.3390/curroncol29100572.
8
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.利用真实世界的基因组数据集评估表皮生长因子受体外显子 20 插入突变的频率、漏诊情况和异质性。
Mol Oncol. 2023 Feb;17(2):230-237. doi: 10.1002/1878-0261.13327. Epub 2022 Nov 28.
9
How to read a next-generation sequencing report-what oncologists need to know.如何解读下一代测序报告——肿瘤医生需要了解的内容
ESMO Open. 2022 Oct;7(5):100570. doi: 10.1016/j.esmoop.2022.100570. Epub 2022 Sep 29.
10
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.联合聚焦下一代测序分析指导实体瘤精准肿瘤学：来自机构分子肿瘤委员会的回顾性分析
Cancers (Basel). 2022 Sep 12;14(18):4430. doi: 10.3390/cancers14184430.
本文引用的文献
1
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.使用决策分析模型比较下一代测序与单基因检测在检测转移性非小细胞肺癌基因组改变中的经济影响
JCO Precis Oncol. 2019 Dec;3:1-9. doi: 10.1200/PO.18.00356.
2
Clinical Use of Precision Oncology Decision Support.精准肿瘤学决策支持的临床应用
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00036. Epub 2017 Sep 13.
3
Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.利用靶向二代测序数据进行可靠的泛癌微卫星不稳定性评估
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00084. Epub 2017 Oct 3.
4
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).一种将基因组改变分级为癌症精准医学治疗靶点的框架：ESMO 分子靶向治疗临床可操作性评分（ESCAT）。
Ann Oncol. 2018 Sep 1;29(9):1895-1902. doi: 10.1093/annonc/mdy263.
5
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.多学科分子肿瘤委员会：一种改善癌症患者临床实践及临床试验入组选择的工具。
ESMO Open. 2018 Jul 23;3(5):e000398. doi: 10.1136/esmoopen-2018-000398. eCollection 2018.
6
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.社区肿瘤学环境中广泛基于基因组测序与晚期非小细胞肺癌患者生存的关联。
JAMA. 2018 Aug 7;320(5):469-477. doi: 10.1001/jama.2018.9824.
7
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature.抗癌药物生物医学文献中罕见应答者的全面综述。
Eur J Cancer. 2018 Sep;101:143-151. doi: 10.1016/j.ejca.2018.06.010. Epub 2018 Jul 27.
8
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.《国家癌症报告：第一部分：全国癌症统计数据》
Cancer. 2018 Jul 1;124(13):2785-2800. doi: 10.1002/cncr.31551. Epub 2018 May 22.
9
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.一线克唑替尼对比化疗用于 ALK 基因突变阳性非小细胞肺癌的研究的最终总生存分析。
J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.
10
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.估算接受基于基因组的肿瘤学治疗的美国癌症患者的百分比。
JAMA Oncol. 2018 Aug 1;4(8):1093-1098. doi: 10.1001/jamaoncol.2018.1660.
Zotero 插件